FDA’s kratom ban would harm the public and damage the agency’s credibility - STAT
FDA’s kratom ban would harm the public and damage the agency’s credibility - STAT — FDA update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 4, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)) should confirm how it applies to their specific situation before acting. There is a time constraint attached: as soon as possible. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA’s kratom ban would harm the public and damage the agency’s credibility - STAT
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B))
What you must do
Review the new rule now and confirm your operation stays compliant to avoid penalties or loss of standing in Pharmaceutical Manufacturing (FDA/DEA).
Deadline
as soon as possible
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- New FDA chief will face COVID woes and calls for drug-approval reform - nature.com
- Pharmaceutical Companies Push Back On ‘Bad Drug’ TV Ads In Tennessee - wpln.org
- Lilly announces $3 billion expansion to injectable drug manufacturing facility for GLP-1 injectables - bioprocessintl.com
- AstraZeneca Completes License Agreement with Dizal for Lung Cancer Treatment Zegfrovy - Contract Pharma
- An interview with John Skerritt, Head of Australia’s TGA - fda.gov